Okanvision Bio-B (01477) announced interim results. The adjusted net loss of $57.523 million decreased by 46.74% year-on-year

Zhitongcaijing · 2d ago

According to the Zhitong Finance App, Okanvision Bio-B (01477) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 424 million yuan, an increase of 44.1% year on year; adjusted net loss of 57.523 million yuan, a year-on-year decrease of 46.74%; and a loss of 0.12 yuan per share.

According to the announcement, the sharp increase in revenue was mainly due to a significant increase in revenue generated from sales of ophthalmic products (including Eusciying®, Colida®, Alaipin®, and products acquired and authorized by Alcon under the Alcon transaction); and a significant increase in royalties revenue based on sales, mainly driven by the successful commercialization of Boyoujing®.